OP
CORT icon

ORG Partners’s Corcept Therapeutics CORT Stock Holding History

ORG Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$278 Hold
8
– – ﹤0.01% 1649
2025
Q3 		$664 Hold
8
– – ﹤0.01% 1440
2025
Q2 		$554 Buy
+8
New +$580 ﹤0.01% 1395

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ORG Partners's CORT Position: Q4 2025 in Review

ORG Partners held its Corcept Therapeutics (CORT) position steady in Q4 2025 at 8 shares worth $278. The position accounts for ﹤0.01% of the portfolio, ranked #1649.

ORG Partners first reported a position in CORT in Q2 2025 and has held it in 3 quarters since. The position peaked at $664 in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • ORG Partners held 8 shares of Corcept Therapeutics worth $278 as of Q4 2025.
  • ORG Partners left its Corcept Therapeutics share count unchanged in Q4 2025.
  • Corcept Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1649 holding.
  • ORG Partners first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • ORG Partners's Corcept Therapeutics position peaked at $664 in Q3 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.